Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt No Debt
CVM's Cash-to-Debt is ranked lower than
99.99% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. CVM: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CVM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4  Med: N/A Max: No Debt
Current: No Debt
Equity-to-Asset 0.45
CVM's Equity-to-Asset is ranked lower than
99.99% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CVM: 0.45 )
Ranked among companies with meaningful Equity-to-Asset only.
CVM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.51  Med: 0.69 Max: 0.99
Current: 0.45
-0.51
0.99
Interest Coverage No Debt
CVM's Interest Coverage is ranked lower than
99.99% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CVM: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CVM' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -40.22
Beneish M-Score: -5.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -8962.99
CVM's Operating Margin % is ranked lower than
99.99% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. CVM: -8962.99 )
Ranked among companies with meaningful Operating Margin % only.
CVM' s Operating Margin % Range Over the Past 10 Years
Min: -190240  Med: -11287.71 Max: -1881.38
Current: -8962.99
-190240
-1881.38
Net Margin % -3655.16
CVM's Net Margin % is ranked lower than
99.99% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. CVM: -3655.16 )
Ranked among companies with meaningful Net Margin % only.
CVM' s Net Margin % Range Over the Past 10 Years
Min: -154060  Med: -5900.65 Max: 6851.63
Current: -3655.16
-154060
6851.63
ROE % -17349.66
CVM's ROE % is ranked lower than
99.99% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. CVM: -17349.66 )
Ranked among companies with meaningful ROE % only.
CVM' s ROE % Range Over the Past 10 Years
Min: -1294.33  Med: -145.02 Max: 48.78
Current: -17349.66
-1294.33
48.78
ROA % -71.81
CVM's ROA % is ranked lower than
99.99% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. CVM: -71.81 )
Ranked among companies with meaningful ROA % only.
CVM' s ROA % Range Over the Past 10 Years
Min: -199.98  Med: -87.01 Max: 25.01
Current: -71.81
-199.98
25.01
ROC (Joel Greenblatt) % -9915.75
CVM's ROC (Joel Greenblatt) % is ranked lower than
99.99% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. CVM: -9915.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CVM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -9588.37  Med: -1101.41 Max: 687.95
Current: -9915.75
-9588.37
687.95
3-Year Revenue Growth Rate -26.30
CVM's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. CVM: -26.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CVM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -21.4 Max: 95.8
Current: -26.3
0
95.8
3-Year EBITDA Growth Rate -9.80
CVM's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CVM: -9.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CVM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -51.5  Med: -9.8 Max: 60.4
Current: -9.8
-51.5
60.4
3-Year EPS without NRI Growth Rate -48.50
CVM's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. CVM: -48.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CVM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51  Med: -11.7 Max: 41.3
Current: -48.5
-51
41.3
GuruFocus has detected 4 Warning Signs with CEL-SCI Corp $CVM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CVM's 10-Y Financials

Financials (Next Earnings Date: 2017-05-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

CVM Guru Trades in

CVM Guru Trades in

CVM Guru Trades in

Q4 2016

CVM Guru Trades in Q4 2016

Jim Simons 689,400 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CVM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:OTCPK:OBMP, NAS:VICL, NAS:HTBX, AMEX:CRMD, NAS:ICCC, NAS:ANTH, OTCPK:PRGB, NAS:NEOT, OTCPK:EMIS, OTCPK:PRNAF, NAS:RPRX, NAS:CATB, NAS:CYTX, NAS:ABIO, NAS:PRTO, NAS:ONCS, NAS:CLRB, OTCPK:USRM, OTCPK:BRTX, OTCPK:GBLX » details
Traded in other countries:LSRN.Germany,
Headquarter Location:USA
CEL-SCI Corp is a biotechnology company. It is engaged in the research & development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system.

CEL-SCI Corp was incorporated on March 22, 1983, in the state of Colorado, to finance research and development in biomedical science and ultimately to engage in marketing and selling products. The Company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. Its investigational therapy, Multikine, is currently being developed as a potential therapeutic agent directed at using the immune system to produce an anti-tumor immune response. Data from Phase 1 and Phase 2 clinical trials suggest that Multikine simulates the activities of a healthy person's immune system, enabling it to use the body's own anti-tumor immune response. Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to review by the U.S. Food and Drug Administration, or FDA, in connection with CEL-SCI's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use. Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines and is manufactured in a proprietary manner in its manufacturing facility. The Company's patented T-cell Modulation Process, referred to as LEAPS (Ligand Epitope Antigen Presentation System), uses heteroconjugates to direct the body to choose a specific immune response. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune, allergies, transplantation rejection and cancer, when it cannot do so on its own. Administered like a vaccine, LEAPS combines T-cell binding ligands with small, disease associated, peptide antigens and may provide a new method to treat and prevent certain diseases.

Ratios

vs
industry
vs
history
PB Ratio 4.29
CVM's PB Ratio is ranked lower than
99.99% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. CVM: 4.29 )
Ranked among companies with meaningful PB Ratio only.
CVM' s PB Ratio Range Over the Past 10 Years
Min: 1.97  Med: 6.86 Max: 280
Current: 4.29
1.97
280
PS Ratio 60.00
CVM's PS Ratio is ranked lower than
99.99% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. CVM: 60.00 )
Ranked among companies with meaningful PS Ratio only.
CVM' s PS Ratio Range Over the Past 10 Years
Min: 35  Med: 301.93 Max: 6850
Current: 60
35
6850
EV-to-EBIT -0.95
CVM's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. CVM: -0.95 )
Ranked among companies with meaningful EV-to-EBIT only.
CVM' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.4  Med: -3.6 Max: 29.5
Current: -0.95
-16.4
29.5
EV-to-EBITDA -0.95
CVM's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. CVM: -0.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
CVM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17  Med: -3.9 Max: 28.1
Current: -0.95
-17
28.1
Current Ratio 1.19
CVM's Current Ratio is ranked lower than
99.99% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. CVM: 1.19 )
Ranked among companies with meaningful Current Ratio only.
CVM' s Current Ratio Range Over the Past 10 Years
Min: 0.17  Med: 7.02 Max: 160
Current: 1.19
0.17
160
Quick Ratio 1.01
CVM's Quick Ratio is ranked lower than
99.99% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. CVM: 1.01 )
Ranked among companies with meaningful Quick Ratio only.
CVM' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 6.94 Max: 160
Current: 1.01
0.04
160
Days Sales Outstanding 5.20
CVM's Days Sales Outstanding is ranked lower than
99.99% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. CVM: 5.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
CVM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.33  Med: 174.48 Max: 505.88
Current: 5.2
48.33
505.88

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -71.30
CVM's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. CVM: -71.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CVM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -71.3  Med: -22.9 Max: -5.3
Current: -71.3
-71.3
-5.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 4.44
CVM's Price-to-Tangible-Book is ranked lower than
99.99% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CVM: 4.44 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CVM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.87  Med: 6.92 Max: 519.17
Current: 4.44
1.87
519.17
Price-to-Median-PS-Value 0.19
CVM's Price-to-Median-PS-Value is ranked lower than
99.99% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. CVM: 0.19 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CVM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.45 Max: 22
Current: 0.19
0.04
22
Earnings Yield (Greenblatt) % -105.26
CVM's Earnings Yield (Greenblatt) % is ranked lower than
100% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. CVM: -105.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CVM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.4  Med: 5.45 Max: 13.9
Current: -105.26
3.4
13.9

More Statistics

Revenue (TTM) (Mil) $0.28
EPS (TTM) $ -0.09
Beta-0.31
Short Percentage of Float4.12%
52-Week Range $0.06 - 0.59
Shares Outstanding (Mil)216.00

Analyst Estimate

Sep17 Sep18
Revenue (Mil $) 2 2
EPS ($) -0.34 0.34
EPS without NRI ($) -0.34 0.34
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CVM

Headlines

Articles On GuruFocus.com
Updated Coverage Report Focuses on CEL-SCI Corporation Jan 12 2015 
Coverage Initiation Report Focuses on CEL-SCI Corporation Oct 15 2014 
CELSCISci Corp Reports Operating Results (10-Q) Feb 09 2011 
CELSCISci Corp Reports Operating Results (10-Q) Aug 16 2010 
CELSCISci Corp Reports Operating Results (10-Q) May 17 2010 
CELSCISci Corp Reports Operating Results (10-Q) Feb 12 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Feb 01 2010 
CELSCISci Corp Reports Operating Results (10-Q/A) Jan 29 2010 
CELSCISci Corp Reports Operating Results (10-K) Jan 13 2010 

More From Other Websites
CEL-SCI Receives Intent to Grant Notice for New Multikine Patent from the European Patent Office Apr 28 2017
CEL-SCI Corporation Releases Letter to Shareholders Apr 24 2017
CEL-SCI Scientist Presents at the World Vaccine Congress Apr 12 2017
CEL-SCI Announces $1.5 Million Registered Direct Offering Mar 09 2017
Blog Coverage CEL-SCI Provides Update on Late-stage Multikine Head and Neck Cancer Study Mar 08 2017
CEL-SCI Gives Update on Partial Clinical Hold on Phase 3 Head and Neck Cancer Study with Multikine Mar 06 2017
Vienna’s Cel-Sci Corp. raises $1 million for head and neck cancer trial Mar 01 2017
CEL-SCI Announces That the NYSE MKT Approves Plan Feb 27 2017
CEL-SCI Scientist Presents New Findings for Rheumatoid Arthritis Treatment Vaccine at Conference Feb 21 2017
Cel-Sci posts 1Q profit Feb 09 2017
CEL-SCI Corporation Reports First Quarter Fiscal 2017 Financial Results Feb 09 2017
CEL-SCI Announces Closing of Public Offering and Receives Audit Opinion with Going Concern... Dec 20 2016
Cel-Sci reports 4Q loss Dec 14 2016
CEL-SCI Reports Fiscal 2016 Financial Results and Clinical & Corporate Developments Dec 14 2016
CEL-SCI Reports on NYSE MKT Noncompliance Notice and Compliance Plan Dec 09 2016
CEL-SCI Announces Pricing of $4.25 Million Public Offering of Common Stock and Warrants Dec 02 2016
CEL-SCI Announces Proposed Public Offering of Common Stock and Warrants Dec 01 2016
CEL-SCI Submits Response to FDA in Connection with Partial Clinical Hold on Phase 3 Clinical Trial Nov 21 2016
CEL-SCI Reports Preclinical Data Showing LEAPS Vaccine is Successful in Treating Rheumatoid... Nov 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)